Patents Assigned to Hepacore Ltd.
  • FGF-2 VARIANTS HAVING N-TERMINAL DELETIONS AND INCREASED RECEPTOR SELECTIVITY AND USES THEREOF
    Publication number: 20180127475
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Application
    Filed: December 12, 2017
    Publication date: May 10, 2018
    Applicants: PROCHON BIOTECH LTD., HEPACORE LTD.
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • FGF-2 variants having N-terminal deletions and increased receptor selectivity and methods of use thereof
    Patent number: 9862753
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: January 9, 2018
    Assignees: PROCHON BIOTECH LTD., HEPACORE LTD
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • CONJUGATES OF CARBOXY POLYSACCHARIDES WITH FIBROBLAST GROWTH FACTORS AND VARIANTS THEREOF
    Publication number: 20170196986
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 13, 2017
    Applicant: HEPACORE LTD.
    Inventors: Avner YAYON, Roy SIRKIS, Boaz AMIT, Avraham WORTZEL
  • Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
    Patent number: 9610357
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: April 4, 2017
    Assignee: HEPACORE LTD.
    Inventors: Avner Yayon, Roy Sirkis, Boaz Amit, Avraham Wortzel
  • FGF-18 truncated variants having increased receptor specificity and uses thereof
    Patent number: 9226949
    Abstract: The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: January 5, 2016
    Assignee: HEPACORE LTD.
    Inventors: Avner Yayon, Eran Rom, Roy Sirkis, Dalit Strauss-Ayali
  • WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF
    Publication number: 20130084278
    Abstract: The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.
    Type: Application
    Filed: November 26, 2012
    Publication date: April 4, 2013
    Applicant: Hepacore Ltd.
    Inventor: Hepacore Ltd.
  • Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
    Patent number: 8329870
    Abstract: The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.
    Type: Grant
    Filed: January 6, 2008
    Date of Patent: December 11, 2012
    Assignee: Hepacore Ltd.
    Inventors: Boaz Amit, Hilla Barkay-Olami, Avner Yayon
  • Methods for bone regeneration using endothelial progenitor cell preparations
    Patent number: 8298528
    Abstract: The present invention relates in general to orthopedics and to a method for promoting repair of large bone defects, in particular non-union or delayed union fractures. Specifically the invention concerns the use of endothelial progenitor cell preparations for bone repair.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: October 30, 2012
    Assignee: Hepacore Ltd.
    Inventors: Avner Yayon, Dina Lewinson, Nimrod Rozen
  • Bone enhancing composite
    Patent number: 7887831
    Abstract: A bone-enhancing composite material comprising synthetic apatite and at least one supplementary bioactive agent selected from a biocompatible polymer and an anti-resorptive agent added ab initio, methods of preparing said composite and uses thereof are provided. The physical and biological properties of the composite are controlled by the addition of specific supplementary bioactive agents as well as optional therapeutic agents. The composite may be used as a powder, a paste or an implant.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: February 15, 2011
    Assignee: Hepacore Ltd.
    Inventor: Avner Yayon
  • METHODS FOR BONE REGENERATION USING ENDOTHELIAL PROGENITOR CELL PREPARATIONS
    Publication number: 20100003222
    Abstract: The present invention relates in general to orthopedics and to a method for promoting repair of large bone defects, in particular non-union or delayed union fractures. Specifically the invention concerns the use of endothelial progenitor cell preparations for bone repair.
    Type: Application
    Filed: April 17, 2007
    Publication date: January 7, 2010
    Applicant: HEPACORE LTD.
    Inventors: Avner Yayon, Dina Lewinson, Nimrod Rozen